Castration-Resistant Prostate Cancer
Androgen deprivation therapy (ADT) has been a mainstay in prostate cancer therapy. After an excellent clinical response to ADT, however, prostate cancer returns as a therapy resistant and deadly form, resulting in a short survival time of 18–24 months. This form of prostate cancer, now known as castration-resistant prostate cancer (CRPC), often metastasizes to the bone and results in the clinical symptoms of pain. A great challenge is the discovery of new chemotherapy drugs that can increase overall survival of patients with recurrent CRPC.